Optimizing the precision oncology workflow at the Bellevue Cancer Center.

Kevin Diasti,Peter Yu,Gaurav Varma,Ahan Bhatt,Jennifer J. Wu

DOI: https://doi.org/10.1200/op.2023.19.11_suppl.416

2023-11-01

JCO Oncology Practice

Abstract:416 Background: Comprehensive tumor molecular profiling using next-generation sequencing (NGS) enables personalized cancer treatment and is standard of care in the management of patients with advanced solid tumors. Efficient implementation of NGS testing into health care systems can be challenging, particularly in safety-net health systems with a high proportion of underserved populations. Here we evaluated the workflow for tissue NGS testing at Bellevue Cancer Center, the tertiary referral center of the NYC Health and Hospitals System. We also investigated the impact of a specimen courier service intervention. Methods: We constructed a process map of the NGS tissue testing workflow to identify key stakeholders and potential sources of delays. Surveys were administered to all NGS ordering clinicians (n=26). Survey questions included time spent ordering NGS testing, how often providers referenced an ordering process guide, and how consistently key steps in the ordering process were completed. Utilization and process data from 2019-2022 was provided by our NGS vendor. The primary measure of process quality was Turn Around Time (TAT) defined as the time from order placement to result report. Secondary measures of process quality included Order to Specimen (OTS) and Specimen to Report (STR), defined as the time from order placement to specimen receipt by the NGS vendor and the time from specimen receipt to result report, respectively. Data were divided into 3-month intervals and median and interquartile range were calculated. We compared TAT, OTS, and STR six months before and after courier service introduction. Data normality was tested using Kolmogorov-Smirnov test and distributions were compared using Mann-Whitney test (Graphpad Prism). A Root Cause Analysis was conducted to identify the causes of delays and opportunities for further workflow optimization. Results: Our findings revealed median TAT from 2019-2022 was 22 days. However, there was a trend towards decreased median TAT in that time period with median TAT of 19 days in 2022. Our analysis demonstrated a decrease in median OTS following courier service introduction (median 8 vs 7 days, p<0.05), but not with overall TAT. STR remained relatively stable throughout the periods of interest. Survey results indicated that only 76.2% of clinicians placed test orders correctly, and 61.9% of clinicians properly notified pathology, both possibly contributing to delays in OTS and TAT. Conclusions: We assessed the complex effort of optimizing the NGS testing workflow at the largest municipal safety net health system in the United States. Courier service implementation improved the OTS but not the overall TAT, suggesting that further interventions will be necessary for improvement in TAT. Survey results identified key inefficiencies in the provider side of the ordering process. Additional interventions such as NGS test integration with electronic health record system may be warranted.

oncology